Ranking of concern, based on environmental indexes, for pharmaceutical and personal care products: an application to the Spanish case.

A wide range of Pharmaceuticals and Personal Care Products (PPCPs) are present in the environment, and many of their adverse effects are unknown. The emergence of new compounds or changes in regulations have led to dynamical studies of occurrence, impact and treatment, which consider geographical areas and trends in consumption and innovation in the pharmaceutical industry. A Quantitative study of Structure-Activity Relationship ((Q)SAR) was performed to assess the possible adverse effects of ninety six PPCPs and metabolites with negligible experimental data and establish a ranking of concern, which was supported by the EPA EPI Suite™ interface. The environmental and toxicological indexes, the persistence (P), the bioaccumulation (B), the toxicity (T) (extensive) and the occurrence in Spanish aquatic environments (O) (intensive) were evaluated. The most hazardous characteristics in the largest number of compounds were generated by the P index, followed by the T and B indexes. A high number of metabolites has a concern score equal to or greater than their parent compounds. Three PBT and OPBT rankings of concern were proposed using the total and partial ranking method (supported by a Hasse diagram) by the Decision Analysis by Ranking Techniques (DART) tool, which was recently recommended by the European Commission. An analysis of the sensibility of the relative weights of these indexes has been conducted. Hormones, antidepressants (and their metabolites), blood lipid regulators and all of the personal care products considered in this study were at the highest levels of risk according to the PBT and OPBT total rankings. Furthermore, when the OPBT partial ranking was performed, X-ray contrast media, H2 blockers and some antibiotics were included at the highest level of concern. It is important to improve and incorporate useful indexes for the predicted environmental impact of PPCPs and metabolites and thus focus experimental analysis on the compounds that require urgent attention.

[1]  M. Haight,et al.  Expert Stakeholders’ Views on the Management of Human Pharmaceuticals in the Environment , 2006, Environmental management.

[2]  J. Brausch,et al.  A review of personal care products in the aquatic environment: environmental concentrations and toxicity. , 2011, Chemosphere.

[3]  A. Bodour,et al.  Prioritizing research for trace pollutants and emerging contaminants in the freshwater environment. , 2010, Environmental pollution.

[4]  Robert S. Boethling,et al.  Predicting ready biodegradability in the Japanese ministry of international trade and industry test , 2000 .

[5]  R. Hannah,et al.  Environmental risk assessment of paroxetine. , 2004, Environmental science & technology.

[6]  Diana S Aga,et al.  Pharmaceutical metabolites in the environment: Analytical challenges and ecological risks , 2009, Environmental toxicology and chemistry.

[7]  Christa S. McArdell,et al.  Consumption and occurrence , 2006 .

[8]  H. Budzinski,et al.  New challenges in environmental analytical chemistry: Identification of toxic compounds in complex mixtures , 2011 .

[9]  T. Ternes,et al.  Pharmaceuticals and personal care products in the environment: agents of subtle change? , 1999, Environmental health perspectives.

[10]  S. Snyder,et al.  Toxicological relevance of pharmaceuticals in drinking water. , 2010, Environmental science & technology.

[11]  R. Brain,et al.  Toxicity classification and evaluation of four pharmaceuticals classes: antibiotics, antineoplastics, cardiovascular, and sex hormones. , 2004, Toxicology.

[12]  Klaus Kümmerer,et al.  The presence of pharmaceuticals in the environment due to human use--present knowledge and future challenges. , 2009, Journal of environmental management.

[13]  Robert S. Boethling,et al.  Group contribution method for predicting probability and rate of aerobic biodegradation. , 1994, Environmental science & technology.

[14]  Beate I. Escher,et al.  Recent advances in environmental risk assessment of transformation products. , 2011, Environmental science & technology.

[15]  J. Garric,et al.  Progestagens for human use, exposure and hazard assessment for the aquatic environment. , 2009, Environmental pollution.

[16]  Frank A. P. C. Gobas,et al.  A review of bioconcentration factor (BCF) and bioaccumulation factor (BAF) assessments for organic chemicals in aquatic organisms , 2006 .

[17]  C. Delerue-Matos,et al.  Ecotoxicological aspects related to the presence of pharmaceuticals in the aquatic environment. , 2010, Journal of hazardous materials.

[18]  A. Al-Ahmad,et al.  Estimation of the cancer risk to humans resulting from the presence of cyclophosphamide and ifosfamide in surface water , 2010, Environmental science and pollution research international.

[19]  D. A. Barry,et al.  Methodology to account for uncertainties and tradeoffs in pharmaceutical environmental hazard assessment. , 2012, Journal of environmental management.

[20]  Y. Perrodin,et al.  Identification and prioritization of bioaccumulable pharmaceutical substances discharged in hospital effluents. , 2012, Journal of environmental management.

[21]  Ettore Zuccato,et al.  Strategic Survey of Therapeutic Drugs in the Rivers Po and Lambro in Northern Italy , 2003 .

[22]  Marion Letzel,et al.  Fate of the antibiotic sulfamethoxazole and its two major human metabolites in a water sediment test. , 2009, Environmental science & technology.

[23]  N Voulvoulis,et al.  Pharmaceuticals in the aquatic environment--a comparison of risk assessment strategies. , 2004, Chemosphere.

[24]  Robert S. Boethling,et al.  Predictive model for aerobic biodegradability developed from a file of evaluated biodegradation data , 1992 .

[25]  Arun Kumar,et al.  Pharmaceuticals, personal care products and endocrine-disrupting chemicals in U.S. surface and finished drinking waters: a proposed ranking system. , 2010, The Science of the total environment.

[26]  F. Gagné,et al.  Occurrence of pharmaceutical products in a municipal effluent and toxicity to rainbow trout (Oncorhynchus mykiss) hepatocytes. , 2006, Ecotoxicology and environmental safety.

[27]  K. Fent,et al.  Ecotoxicology of human pharmaceuticals. , 2006, Aquatic toxicology.

[28]  Rainer Brüggemann,et al.  A Comparison of Partial Order Technique with Three Methods of Multi-Criteria Analysis for Ranking of Chemical Substances , 2002, J. Chem. Inf. Comput. Sci..

[29]  G. Streck.  Chemical and biological analysis of estrogenic, progestagenic and androgenic steroids in the environment , 2009 .

[30]  E. Cooper,et al.  Preliminary risk assessment database and risk ranking of pharmaceuticals in the environment. , 2008, The Science of the total environment.

[31]  John D. Walker,et al.  Use of QSARs in international decision-making frameworks to predict health effects of chemical substances. , 2003, Environmental health perspectives.

[32]  Despo Fatta-Kassinos,et al.  Pharmaceutical residues in environmental waters and wastewater: current state of knowledge and future research , 2011, Analytical and bioanalytical chemistry.

[33]  Hans Sanderson,et al.  Ranking and prioritization of environmental risks of pharmaceuticals in surface waters. , 2004, Regulatory toxicology and pharmacology : RTP.

[34]  D. Barceló,et al.  Endocrine disruptors in sewage treatment plants, receiving river waters, and sediments: Integration of chemical analysis and biological effects on feral carp , 2002, Environmental toxicology and chemistry.

[35]  S. Meriç,et al.  Occurrence patterns of pharmaceuticals in water and wastewater environments , 2007, Analytical and bioanalytical chemistry.

[36]  M. Gavrilescu,et al.  Pharmaceuticals, Personal Care Products and Endocrine Disrupting Agents in the Environment – A Review , 2009 .

[37]  S. McGrath,et al.  Low biodegradability of fluoxetine HCl, diazepam and their human metabolites in sewage sludge-amended soil , 2008 .

[38]  D. Barceló,et al.  Removal of pharmaceuticals during wastewater treatment and environmental risk assessment using hazard indexes. , 2010, Environment international.

[39]  M Verwei,et al.  Development of a QSAR for worst case estimates of acute toxicity of chemically reactive compounds. , 2007, Toxicology letters.

[40]  T. Heberer.  Occurrence, fate, and removal of pharmaceutical residues in the aquatic environment: a review of recent research data. , 2002, Toxicology letters.

[41]  Manuela Pavan,et al.  Review of QSAR Models for Ready Biodegradation , 2006 .

[42]  Rainer Brüggemann,et al.  Ranking of pharmaceuticals detected in the environment: aggregation and weighting procedures. , 2008, Combinatorial chemistry & high throughput screening.

[43]  Robert Boethling,et al.  Chemical structure-based predictive model for methanogenic anaerobic biodegradation potential. , 2007, Environmental toxicology and chemistry.

[44]  B. Brooks,et al.  Active Pharmaceutical Ingredients andAquatic Organisms , 2011 .

[45]  P. G. Encina,et al.  Consumption and occurrence of pharmaceutical and personal care products in the aquatic environment in Spain. , 2013 .

[46]  Thorsten Reemtsma,et al.  Pathways and metabolites of microbial degradation of selected acidic pharmaceutical and their occurrence in municipal wastewater treated by a membrane bioreactor. , 2005, Water research.

[47]  Werner Brack,et al.  MODELKEY. Models for assessing and forecasting the impact of environmental key pollutants on freshwater and marine ecosystems and biodiversity (5 pp) , 2005, Environmental science and pollution research international.

[48]  Manuela Pavan,et al.  A set of case studies to illustrate the applicability of DART (Decision Analysis by Ranking Techniques) in the ranking of chemicals , 2008 .

[49]  D. Barceló,et al.  Environmental risk assessment of pharmaceuticals in rivers: relationships between hazard indexes and aquatic macroinvertebrate diversity indexes in the Llobregat River (NE Spain). , 2010, Environment international.

[50]  T. Ternes,et al.  Determination of neutral pharmaceuticals in wastewater and rivers by liquid chromatography-electrospray tandem mass spectrometry. , 2001, Journal of chromatography. A.

[51]  Thomas Knacker,et al.  Evaluation of Measured and Predicted Environmental Concentrations of Selected Human Pharmaceuticals and Personal Care Products (10 pp) , 2006, Environmental science and pollution research international.

[52]  Anna-Karin Johansson,et al.  Are pharmaceuticals potent environmental pollutants? Part I: environmental risk assessments of selected active pharmaceutical ingredients. , 2006, The Science of the total environment.

[53]  Yaqi Cai,et al.  Occurrence, distribution and bioaccumulation of antibiotics in the Haihe River in China. , 2012, Journal of environmental monitoring : JEM.

[54]  A. Alves,et al.  Amoxicillin degradation at ppb levels by Fenton's oxidation using design of experiments. , 2010, The Science of the total environment.